Lightnews — Scholar-powered news

Reposted by Pratiti (Mimi) Bandopadhayay

Beroukhim Lab @rameenberoukhim.bsky.social · 23d

This was a fun project with John Rhee and Charlotta Lindvall on using LLMs to scour medical records. It has been wonderful to work with them!
secure-web.cisco.com/1QgAtJ9SFoCj...

Scalable Tracking of Symptoms in the Electronic Health Record using Large Language Models in Patients with Central Nervous System Cancers Undergoing Therapy

AbstractBackground. Advances in large language models (LLMs) provide a means for scalable tracking of patient symptoms in clinical trials and post-marking

secure-web.cisco.com

1 3

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Sep 3

Everyone needs to watch this. Our children deserve better. They need MORE funding, resources and research. Not less. lnkd.in/gevV3Gth

#pediatriccancerawareness | René Marsh

Federal funding for a pediatric brain cancer network of top doctors, scientists and hospitals across the country is being cut. Health and Human Services tells CNN the cut is for efficiency. The Pedi...

lnkd.in

4

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Aug 30

www.nytimes.com/2025/08/28/w...

Pediatric Brain Cancer Group to Lose Federal Funding

www.nytimes.com

3

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Aug 23

Excited to get this out there as we go through revisions. These findings have changed how I think about KIAA1549-BRAF of pediatric gliomas, and all other fusions, completely.

The fusion partner is important, necessary and engenders novel vulnerabilities that can be therapeutically targeted.

Adnan Halim @manno.se · Aug 23

Together with @glyco.me, @bandolab.bsky.social and teams, we recently uncovered a link between pediatric brain tumors, POMT1/2 enzymes and KIAA1549 - full story in the preprint below:

www.biorxiv.org/content/10.1...

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actio...

www.biorxiv.org

1 3

Reposted by Pratiti (Mimi) Bandopadhayay

Brent Orr @baoflex.bsky.social · Aug 20

Terrible news for pediatric brain tumor research and incredible amount of hard work wasted. This very likely will result in some active trials prematurely closing without sufficient accrual to answer their aims.

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Aug 19

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better

1 1 3

Reposted by Pratiti (Mimi) Bandopadhayay

Beroukhim Lab @rameenberoukhim.bsky.social · Aug 20

Every dollar invested by the federal government on health research returns $2.60 in economic activity, not to mention the benefits to our health. The federal government spends very little on biomedical research as it is; it is so counterproductive to cut what remains. ☹️

1 3

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Aug 19

Devastating news. The Pediatric Brain Tumor Consortium has lost its ability to apply for federal funding upon which it is structured. Without this, it cant exist. This threatens access to clinical trials for children.
These children need MORE funding and MORE trials, not less.
They deserve better

2 15 19

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Jul 31

Excited to share our paper reporting significance of FGFR-alterations across pediatric gliomas. Congratulations April Apfelbaum and Eric Morin and to everyone across our labs and collaborators. Thank you to the foundations and patients/ families who made this happen. www.bandolab.org
rdcu.be/eyHcG

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas

Nature Communications - A subset of pediatric gliomas harbour alterations in fibroblast growth factor receptor (FGFR)-family proteins. Here, the authors characterise the genomic landscape of 11,635...

rdcu.be

1 1 4

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · May 21

Excited to be part of the editorial team for the FIRST journal specifically focused on pediatric brain tumors. Submissions now open!

EANO @eanoassociation.bsky.social · May 21

💪Neuro-Oncology Pediatrics – a new open access journal by EANO & @neuroonc.bsky.social for the global #pediatric & AYA #NeuroOncology community. Now open for submissions!
🔗 academic.oup.com/neuro-onc-peds
Editor-in-Chief: S. Mueller
Executive Editors: M. A. Roldán (EANO), @bandolab.bsky.social (SNO)

2 4 12

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · May 15

An inspirational (and fun) few days of science at the joint Bando-Beroukhim-Ligon Labs retreat in Maine. Joined by Nada Jabado, Claudia Kleinman and Veronica Rendo. We are all on the mission together to find better treatments for our kids #BandoLab

5

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Mar 20

A fun project with @rameenberoukhim.bsky.social and @vrendo.bsky.social focused on how the interplay between structural variants at the BRD4 locus fine tunes its expression. Congratulations to Jeremiah, Simona, Sophie and team, and also to Veronica! Looking forward to many more collaborations ahead.

Veronica Rendo @vrendo.bsky.social · Mar 19

📣 Online now! Our study shows how recurrent focal deletions constitute a mechanism by which cancer cells can dampen toxicity due to gene amplification.

www.cell.com/cell-genomic...

🧵👇:

Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification

Wala et al. identify recurrent focal BRD4 deletions in tumors harboring larger amplifications, suggesting that these deletions may serve to limit toxic BRD4 overexpression. A CRISPR-Cas9 cell line mod...

www.cell.com

4

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Feb 27

Congratulations to @vrendo.bsky.social. Very excited for the amazing science that is still to come from the Rendo Lab for our kids with brain tumors

Veronica Rendo @vrendo.bsky.social · Feb 27

Today we celebrated my official Group Leader appointment and paper publications with bubbles and prinsesstårta, the Swedish way! 🍰🥂🍾 Skål!

1 2

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Feb 27

The Bando and Beroukhim Labs (www.bandolab.org, www.beroukhimlab.org) are seeking a Senior Scientist to help find better treatments for children with brain tumors. More details here: careers.dana-farber.org/job/11089/sr...

@rameenberoukhim.bsky.social #BandoLab #DFCI @broadinstitute.org

Research Laboratory Job: Sr Scientist - Bandopadhayay Lab at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA

Sr Scientist - Bandopadhayay Lab job

careers.dana-farber.org

3 8

Reposted by Pratiti (Mimi) Bandopadhayay

Veronica Rendo @vrendo.bsky.social · Feb 19

So excited to see this paper out! An example of how window of opportunity trials can help dissect the mechanisms of response and resistance associated with targeted therapies in glioblastoma 🧠
www.science.org/doi/10.1126/...
Thanks to the patients and scientific team who made this study possible.

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

In patients with glioblastoma, navtemadlin resistance is not mediated by TP53-inactivating mutations, and combination with TMZ may improve efficacy.

www.science.org

1 5

Reposted by Pratiti (Mimi) Bandopadhayay

Nick Vitanza @nickvitanza.bsky.social · Feb 6

With an aim to drive collaborative team science & in honor of our remarkable #CARTcell patients, we started the annual Cleveland Hood Lecture w/ Dr Neev Manoharan of Sydney Children’s Hospital as our inaugural speaker. It’s a privilege to build intercontinental alliances against childhood cancer ❤️🔬

1 9

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Feb 2

Congratulations to @johnprensner.bsky.social and the entire team!

John Prensner @johnprensner.bsky.social · Feb 2

Looking to see how #RiboSeq can improve your cancer research?

Check out how we've been developing new methods to study #medulloblastoma and other forms of #childhoodcancer.

Out in @naturecomms.bsky.social now. Thanks to Jim Clauwaert and Gerben Menschaert as well!

www.nature.com/articles/s41...

Deep learning to decode sites of RNA translation in normal and cancerous tissues - Nature Communications

RNA translation is a core cell process that is deregulated in cancer. Here, the authors show that a machine learning approach, RiboTIE, can reconstruct RNA translation in cancer and non-cancer cells. ...

www.nature.com

1

Reposted by Pratiti (Mimi) Bandopadhayay

Nick Vitanza @nickvitanza.bsky.social · Jan 28

Honored to have our recently published first-in-human phase 1 clinical trial of repeatedly dosed intracerebroventrocular B7-H3 #CARTcells for children with #DIPG highlighted in @theaacr.bsky.social and #CancerDiscovery Research Watch ❤️🔬

BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG

Main Finding: A phase I trial supported the safety and feasibility of repeated intracranial infusions of B7-H3 CAR T cells for DIPG.Concept: B7-H3 is an immunoregulatory protein expressed on the surfa...

aacrjournals.org

2 9 41

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Jan 28

Proud to share this preprint on behalf of Nico, Daren and team with some insights that we hope will be helpful to those modeling K27M mutations in histone proteins. #BandoLab

www.biorxiv.org/content/10.1...

N-terminal modification of Histone H3 inhibits H3K27M-mediated loss of H3K27 trimethylation

The use of short epitope tags is widespread in the study of histone H3 biology as they allow for the antibody-mediated detection and pulldown of particular histone post-translational modifications (PT...

www.biorxiv.org

1 9

Reposted by Pratiti (Mimi) Bandopadhayay

Mark Dawson @mafdawson.bsky.social · Jan 2

Why can a human tolerate a drug that globally inhibits transcription? Why do transcription inhibitors not cure cancer? Our first paper of 2025 may help explain (some) of this!

So incredibly proud of @tobiaswilliams.bsky.social & Ewa Michalak who led the work!

www.cell.com/molecular-ce...

mRNA export factors store nascent transcripts within nuclear speckles as an adaptive response to transient global inhibition of transcription

Transcription inhibitors also disrupt nuclear export. Here, Williams et al. reveal that mRNA export factors sense transcription inhibition and adapt by storing mature export-competent mRNA in nuclear speckles. This enables rapid release when transcription resumes and ensures retention of cellular identity and viability during a transient global transcription insult.

www.cell.com

10 72 200

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 23

A proud mentor moment! Congratulations to Jenna! We are so excited to have you in our team and working for children with brain tumors to find more effective and less toxic treatments.

Www.bandolab.org @broadinstitute.org #DFCI #SNO2024 #ISPNO

14

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 22

Thanks for including me!

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 21

#SNO2024…… my first BlueSky meeting! Excited to connect with friends, colleagues and collaborators and brainstorm around our projects focused on pediatric brain tumors. Www.bandolab.org #teamscience #PedBrainTumors #BandoLab #DFCI @broadinstitute.org

We are on this mission together

1 11

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 18

Ditto back to you and the Prensner Lab!

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 18

Our Blue Skies repost of April and Eric's preprint, on behalf of the www.bandolab.org, Ligon Lab, David Jones, and collaborators, focused on FGFR-alterations in pediatric gliomas. #TeamScience #PedBrainTumors @broadinstitute.bsky.social #DanaFarber @dkfz.bsky.social

www.biorxiv.org/content/10.1...

A diverse landscape of FGFR alterations and co-mutations defines novel therapeutic strategies in pediatric low-grade gliomas

Alterations in Fibroblast growth factor receptor (FGFR)-family proteins frequently occur as oncogenes in many cancers, including a subset of pediatric gliomas. Here, we performed a genomic analysis of...

www.biorxiv.org

1 2 7

Pratiti (Mimi) Bandopadhayay @bandolab.bsky.social · Nov 11

Hello to the Blue Sky community! Excited to join on behalf of www.bandolab.org! We are on a mission to find more effective and less toxic treatments for children with brain tumors

Bandopadhayay Lab at Dana-Farber Cancer Institute

The Bandopadhayay Lab applies genomics to characterize driver alterations that contribute to pediatric brain tumor formation and to develop strategies to therapeutically target them.

www.bandolab.org

2 1 8